Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
Jean‐Pierre J. Issa(Fox Chase Cancer Center), Gail J. Roboz(New York Hospital Queens), David A. Rizzieri(Duke Medical Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Wendy Stock(University of Chicago), Casey L. O’Connell(University of Southern California), Karen Yee(Princess Margaret Cancer Centre), Raoul Tibes(Mayo Clinic in Arizona), Elizabeth A. Griffiths(Roswell Park Comprehensive Cancer Center), Katherine Walsh(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Naval Daver(The University of Texas MD Anderson Cancer Center), Woonbok Chung(Temple University), Sue Naim(Astex Pharmaceuticals), Pietro Taverna(Astex Pharmaceuticals), Aram Oganesian(Astex Pharmaceuticals), Yong Hao(Astex Pharmaceuticals), James N. Lowder(Astex Pharmaceuticals), Mohammad Azab(Astex Pharmaceuticals), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center)
Cited by 281Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis